RETATRUTIDE

Retatrutide  is a synthetic peptide with 99.5% purity that functions as a triple receptor agonist, targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

Its molecular structure adopts a single continuous helical conformation, enabling the N-terminal segment to engage the receptor transmembrane domain while the C-terminal segment interacts with extracellular regions of the GLP-1 and GIP receptors. Retatrutide exhibits differential potency, with an EC₅₀ of 0.0643 nM at the human GIP receptor, 0.775 nM at the GLP-1 receptor, and 5.79 nM at the glucagon receptor.

The peptide demonstrates dose-dependent pharmacological activity and has a half-life of approximately six days. It undergoes primarily hepatic metabolism without significant interaction with cytochrome P450 enzymes. Retatrutide’s receptor activation leads to measurable changes in metabolic parameters, including reductions in gastric emptying and food intake. These effects contribute to alterations in body weight and glycated hemoglobin levels in experimental models.